MoneyWorks4Me

Zydus Lifesciences informs about press release

19 Jan 2024 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated January 19, 2024 titled ‘Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets (generic version of IBRANCE®) for the US market. 

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1106.70 -10.30 (-0.92%)
19-Aug-2026 13:55 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1894.90
Dr. Reddys Labs. 1175.20
Cipla 1417.80
Lupin 2219.90
Zydus Lifesciences 1106.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: